- Unicycive Therapeutics press release (UNCY): Q3 GAAP EPS of -$0.46 beats by $0.07.
- As of September 30, 2025, cash and cash equivalents totaled $42.7 million. The Company believes that it has a cash runway into 2027.
Unicycive Therapeutics GAAP EPS of -$0.46 beats by $0.07 (NASDAQ:UNCY)
